<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513994</url>
  </required_header>
  <id_info>
    <org_study_id>07-002</org_study_id>
    <nct_id>NCT00513994</nct_id>
  </id_info>
  <brief_title>MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects</brief_title>
  <official_title>MQX-503 Applied to the Fingers vs. Nitroglycerin Ointment 2%, USP, Applied to the Chest: A Pharmacokinetic Comparison in Normal Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediQuest Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediQuest Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to measure how much nitroglycerin or its metabolites may be found
      in the bloodstream when MQX-503 or an FDA approved Nitroglycerin ointment 2% USP is applied
      to the skin of healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is the measurement and comparison of the levels of nitroglycerin and its metabolites in the blood of healthy human volunteers after a single topical dose of MQX-503 and a single topical dose of Nitroglycerin Ointment 2%, USP.</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary objective is the observation of the volunteers for any adverse events</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MQX-503, Nitro-Bid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers 18 - 70 years of age.

          -  Subjects able to give written informed consent and comply with study requirements.

          -  Subjects willing and able to safely discontinue all current prescription therapies.

          -  Subjects who will agree not to participate in other clinical trials.

          -  Negative pregnancy test in fertile females and agreement to use effective
             contraception throughout the study.

        Exclusion Criteria:

          -  Persons who would be put at risk by discontinuing prescription therapies.

          -  Subjects with a known allergy to nitroglycerin.

          -  Subjects who have a condition or issue that would adversely affect the application of
             study medication, study evaluations or the subject's ability to comply with the
             protocol.

          -  Subjects who recently experienced myocardial infarction, uncontrolled congestive heart
             failure, unstable angina, uncontrolled hypotension or uncontrolled hypertension.

          -  Subjects who have participated in a study of an investigational drug within two weeks
             of visit 1.

          -  Subjects who have screening lab values that are out of range or are considered
             clinically significant by the investigator.

          -  Subjects who have had major abdominal, thoracic, or vascular surgery within 6 months
             of visit 1.

          -  Subjects with non-epithelialized skin lesions or interfering skin conditions at the
             time of screening in the area where study medication is to be applied.

          -  Pregnant or nursing women.

          -  Women of childbearing potential who are unwilling to comply with the contraceptive
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adel Nada, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles River Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles River Clinical Services</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>April 8, 2008</last_update_submitted>
  <last_update_submitted_qc>April 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Nitroglycerin</keyword>
  <keyword>pharmacokinetics study of nitroglycerin containing treatments</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

